Electra Therapeutics to Present ELA026 Data at 2024 EHA Congress

Electra Therapeutics, Inc., a biotech firm in the clinical stage of developing antibody therapies, has announced that its leading drug candidate, ELA026, will be featured in a late-breaking oral session at the European Hematology Association (EHA) Congress. The event is scheduled to take place in Madrid, Spain, and will also be live-streamed from June 13 to 16, 2024.

ELA026 and Its Potential Impact on sHLH

The focus of the oral presentation will be the clinical data from a Phase 1b study of ELA026, aimed at treating secondary hemophagocytic lymphohistiocytosis (sHLH). This is a rare, severe hyperinflammatory disease for which no approved treatment exists. ELA026, a monoclonal antibody, targets various forms of the signal regulatory protein (SIRP), specifically SIRP-α, β1, and γ. This targeting allows for the precise elimination of pathological immune cells.

Details of the Presentation

The oral presentation, titled "ELA026 Targeting of SIRP(+) Immune Cells Results in a High Response Rate and Improved 2-Month Survival of Treatment-Naïve Malignancy-Associated Hemophagocytic Lymphohistiocytosis in a Phase 1 Study," will be delivered by Dr. Abhishek Maiti. Dr. Maiti is an Assistant Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center. The session will occur on Sunday, June 16, 2024, from 9:45 to 11:15 a.m. Central European Summer Time at the Madrid Recinto Ferial Hall Picasso, and it will also be available on the EHA Congress platform. The abstract for this oral presentation is coded LB3442 and is available on the EHA website.

Understanding Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

sHLH is a severe inflammatory condition with no existing approved treatments. It can be triggered by various factors, including cancer (malignancy-associated HLH or mHLH), infections, autoimmune diseases, or immunotherapy. The disease is characterized by a systemic inflammatory response that necessitates immediate medical intervention. If not treated, patients can suffer from multiple organ failures and ultimately face death. The mortality rate is particularly high in the early stages after diagnosis, with mHLH patients having the most unfavorable outcomes.

About Electra Therapeutics

Electra Therapeutics is a biotechnology company focused on developing therapies targeting novel disease mechanisms across a wide range of immunological conditions and cancers. The company's leading product, ELA026, is a monoclonal antibody designed to target SIRP present on myeloid cells and T lymphocytes, thereby effectively depleting pathological immune cells. ELA026 is currently in clinical development for treating sHLH, as well as other potential disease indications.

In summary, Electra Therapeutics is set to present promising clinical data on its drug candidate ELA026 at the upcoming EHA Congress. The presentation will provide insights into the potential of ELA026 to address the currently unmet medical needs of patients suffering from sHLH, a life-threatening hyperinflammatory disease.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!